• Advisory committee voted 10 for and 4 against that evidence from the Phase III MOVE study show palovarotene is an effective treatment in patients with the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP)
• Advisory committee further voted 11 for and 3 against on the benefits of palovarotene outweighing the risks, for the treatment of patients with FOP
• FDA PDUFA action date is anticipated by August 16, 2023

Ipsen clearly wants to be a big deal in the rare bone disease fibrodysplasia ossificans progressiva (Fop). But its move to license BLU-782 from Blueprint Medicines today raises questions about the $1bn it paid for Clementia in February. BLU-782 targets the genetic cause of Fop so could presumably risk making palovarotene, which Ipsen gained through Clementia, redundant. 

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) climbed $4.16 (40%) to $14.50 on Wednesday after announcing regulatory plans for palovarotene that could put the therapy first in line to gain FDA approval for fibrodysplasia ossificans progressiva (FOP). Clementia announced the news after market close Tuesday.